LNA
Qiagen Makes $100M Bid to Acquire Exiqon
Qiagen has submitted an offer to buy all of Exiqon's shares for DKK18 each, for a total aggregate purchase price of DKK683 million ($103.5 million).
Roche is moving forward with Santaris' LNA-based antagonist of HIF-1 alpha, but has not decided on the future of a Phase II microRNA-target HCV drug candidate.
This story has been updated to include additional comment from Roche.
A team led by researchers from Massachusetts General Hospital and Santaris Pharma this week published new data showing that inhibition of the microRNA-33 family using short locked nucleic acids could impact cholesterol levels in non-human primates without triggering any adverse e
Santaris Pharma said this week that partner Enzon has returned the rights to all of the data and intellectual property related to the locked nucleic acid drugs the companies were developing under a long-term partnership in cancer.
Jul 11, 2013
Apr 18, 2013
Apr 11, 2013
Apr 11, 2013
Mar 21, 2013
Sep 27, 2012
Jun 14, 2012
Jun 7, 2012
Apr 19, 2012
Mar 29, 2012
Mar 22, 2012
Feb 2, 2012
Jan 12, 2012
Dec 15, 2011
Dec 1, 2011